« Return to News | CROs/Service Providers

Theorem expands partnership with Medidata

Wednesday, March 13, 2013 11:08 AM

Theorem Clinical Research, a midsized full-service, global CRO, has expanded its Medidata services partnership by obtaining accreditation for Medidata Balance and Medidata Rave Targeted Source Document Verification (TSDV) services.

Medidata Balance accreditation enables Theorem to provide a unified approach to patient data capture and randomization. Clinical investigators and sponsors will gain immediate operational efficiencies while leveraging Theorem’s clinical expertise.

“We will be able to transform what can be a lengthy and expensive process into a fast implementation on one platform for subject randomization, supply dispensation and clinical data entry and reporting,” said Mark Penniston, senior vice president for clinical analytics, Theorem.

Theorem also will provide more efficient monitoring services by executing targeted, risk-based source document verification by implementing Medidata Rave TSDV.

“This will help us reduce monitoring costs while improving data quality for our sponsors,” Penniston explained.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.